Zymeworks Stock Price - ZYME

0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Zymeworks Inc ZYME NYSE Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.03 0.07% 40.45 40.255 43.00 40.55 40.42 20:00:00
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,671 217,668 $ 41.37 $ 9,005,064 482,116 14.05 - 52.75
Last Trade Time Type Quantity Stock Price Currency
18:30:00 4,294 $ 40.45 USD

Zymeworks Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.84B 45.48M $ -36.56M -1.27 - 38.88M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
531.99k $ - 0.00% - -

more financials information »

Zymeworks News

Loading Messages....

Latest ZYME Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ZYME Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week48.5149.5039.9543.60286,530-8.06-16.62%
1 Month44.5449.5839.9545.67263,706-4.09-9.18%
3 Months43.1452.7535.8145.23426,192-2.69-6.24%
6 Months25.1152.7523.7638.62366,42915.3461.09%
1 Year14.9852.7514.0532.10290,78125.47170.03%
3 Years13.5052.756.2526.42152,42026.95199.63%
5 Years13.5052.756.2526.42152,42026.95199.63%

Zymeworks Description

Zymeworks Inc is a clinical-stage ccompany. It is dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's product candidate, ZW25, is a bispecific (dual-targeting) antibody being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2. Its design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.